



The effect of osteoporosis and its treatment on fracture healing a systematic review of animal and clinical studies

E.A. Gorter^{a,*}, C.R. Reinders^a, P. Krijnen^a, N.M. Appelman-Dijkstra^b, I.B. Schipper^a

^a Leiden University Medical Center, Departments of Trauma Surgery, P. O. Box 9600, 2300 RC Leiden, the Netherlands

^b Internal Medicine, Center for Bone Quality, P. O. Box 9600, 2300 RC Leiden, the Netherlands

ARTICLE INFO

Keywords:

Osteoporosis
Bisphosphonates
Teriparatide
Fracture healing
Non-union
Delayed-union

ABSTRACT

Introduction: Osteoporosis is characterised by low bone mass and micro-architectural deterioration of bone structure. Its treatment is directed at the processes of bone formation or resorption, that are of utmost importance in fracture healing. We provide a comprehensive review of the literature aiming to summarize and clarify the effects of osteoporosis and its treatment on fracture healing.

Material and methods: A literature search was conducted in PubMed and Embase (OVID version). In vivo animal and human studies on long bone fractures were included. A total of 93 articles were included for this review; 23 studies on the effect of osteoporosis (18 animal and 5 clinical studies) and 70 studies on the effect of osteoporosis treatment (41 animal, 26 clinical studies and 3 meta-analyses) on fracture healing.

Results: In animal fracture models osteoporosis was associated with decreased callus formation and bone growth, bone mineral density, biomechanical strength and delayed cellular and differentiation processes during fracture healing. Two large databases identified osteoporosis as a risk factor for non-union whereas three other studies did not. One of those three studies however found a prolonged healing time in patients with osteoporosis. Anti-osteoporosis medication showed inconsistent effects on fracture healing in both non-osteoporotic and osteoporotic animal models. Only the parathyroid hormone and anti-resorption medication were related to improved fracture healing and delayed remodelling respectively. Clinical studies performed in predominantly hip and distal radius fracture patients showed no effect of bisphosphonates on fracture healing. Parathyroid hormone reduced time to union in several clinical trials performed in mainly hip fracture patients, but this did not result in decreased delayed or non-union rates.

Conclusion: Evidence that substantiates the negative influence of osteoporosis on fracture healing is predominantly from animal studies and to a lesser extent from clinical studies, since convincing clinical evidence lacks. Bisphosphonates and parathyroid hormone may be used during fracture healing, since no clear negative effect has been shown. Parathyroid hormone might even decrease time to fracture union, without decreasing union rate.

1. Introduction

Fracture healing is a result of an orchestrated process on cellular and molecular level, and can be divided in direct (primary) and indirect (secondary) fracture healing [1–4]. Direct fracture healing occurs when the fractured parts are anatomically reduced, compressed and rigidly fixated. Indirect fracture healing occurs via four stages in a situation where (micro) movement of the fracture fragments is possible. The four stages are inflammatory response, soft callus formation, hard callus formation and bone remodelling. For both types of fracture healing four

elements are essential in order to achieve fracture union: osteogenic cells, the (mechanical) environment, osteoconductive scaffolds and growth factors [4]. Osteoporosis is considered as a possible risk factor for impaired fracture union. Although the mechanical and biological elements involved in fracture healing are affected by osteoporosis, there is still debate whether and to what extent fracture healing might be impaired by osteoporosis [5,6].

Osteoporosis is a skeletal disorder that is characterised by low bone mass and micro-architectural deterioration of bone structure, resulting in bone fragility and an increased fracture risk [6]. The prevalence of

* Corresponding author at: Leiden University Medical Center, Department of Trauma Surgery, postzone K6-R, P. O. Box 9600, 2300 RC Leiden, the Netherlands.
E-mail address: e.a.gorter@lumc.nl (E.A. Gorter).

<https://doi.org/10.1016/j.bonr.2021.101117>

Received 3 June 2021; Received in revised form 25 July 2021; Accepted 10 August 2021

Available online 16 August 2021

2352-1872/© 2021 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY license (<http://creativecommons.org/licenses/by/4.0/>).

osteoporosis increases with age. Osteoporotic fractures pose an increasing burden on the healthcare system, since the annual number of osteoporotic fractures will rise to 4.5 million in 2025 in the European Union [7] and is estimated to be around 18 million globally in 2040 [8]. In addition, osteoporotic fractures are associated with high rates of morbidity and mortality [8]. Osteoporosis reduces bone strength because cortical bone becomes porous and cortices become thinner, especially in the metaphyseal or metadiaphyseal regions. Unstable and comminuted fracture patterns, short epiphyseal fragments that complicate fracture fixation, impaired healing due to either too unstable or too rigid fixation, decreased holding power of screws in the osteoporotic bone and early implant-bone construct fatigue are biomechanical problems that may lead to implant loosening and loss of fixation in osteoporotic fractures [8]. These potential problems in fracture management add to the effect of osteoporosis on mechanical and biological elements involved in the healing process as described above.

Anti-osteoporotic drugs, especially antiresorptive therapy, are the cornerstone of treatment for osteoporosis. Their anti-resorptive effect has been posed to negatively influence fracture healing while anabolic therapies like teriparatide have been used in studies trying to enhance fracture healing. As literature provides conflicting evidence, we aimed to perform a systematic review of the current literature to elucidate the role of osteoporosis and osteoporosis treatment as potential risk factors for impaired fracture healing in long bone fractures in animal and clinical studies.

2. Material and methods

The following search strategy was used in Pubmed: “(“Osteoporosis”[Mesh] OR “Osteoporosis, Postmenopausal”[Mesh] OR osteoporosis [tiab]) AND (“Fracture Healing”[Mesh] OR fracture healing [tiab])”, and

in Embase (OVID version) “fracture healing.mp AND Osteoporosis.ab, ti.”. The search was conducted at the first of November 2020 and the results were limited to English language articles. Duplicates were removed before applying selection criteria. Two investigators (EAG and CRR) independently assessed the identified titles and abstracts for relevance.

Only in vivo animal, human studies and meta-analyses on long bone fractures were considered for inclusion. In case of animal studies only articles describing an effect of osteoporosis and/or anti-osteoporotic medication on the histological, biomechanical, radiological and/or clinical process of fracture healing were included. Only clinical studies that reported on one or more of the following outcome parameters were included: (radiographic) time to union, incidence of delayed/non-union or union rate. In case of multiple meta-analyses on the same subject, the most recent meta-analysis was included. The full-text articles of potentially eligible studies were obtained and screened using the same inclusion criteria. Reference lists of eligible studies, reviews and meta-analyses were hand-searched to identify further relevant studies meeting the inclusion criteria. The data extraction was performed by one reviewer (EAG).

Regarding the effect of medication on fracture healing, the results/studies were subdivided based on the mechanism of action (anti-resorptive, anabolic or dual), medication group and whether the medication was supplemented in a non osteoporotic or osteoporotic animal model. The article selection process is presented in Fig. 1. The search resulted in a total of 2625 articles, 1055 PubMed and 1570 Embase. After removal of 678 duplicates and 351 conference abstracts, the title and abstract of 1596 articles were screened. Of 168 articles the full text was read. A total of 93 articles were included for this review.




Fig. 1. Number and type of studies resulting from the literature search.

3. Results

The results of the 93 included publications are summarized in the Tables 1,2, 3 and 4.

3.1. Effect of osteoporosis on fracture healing - animal studies (Table 1)

A total of 18 prospective animal studies were found describing the effect of osteoporosis on fracture healing. Overall, in animal studies osteoporosis was found to negatively influence fracture healing in the majority of studies. Delayed cellular processes, decreased callus formation and mineralization may be the possible explanation of the observed decrease of biomechanical strength. No clear effect of osteoporosis was found in radiological follow-up.

In mice, the effect of osteoporosis on the fracture healing of the femur was investigated, the micro-CT analysis showed impaired healing in the osteoporotic group [9]. In another genetic osteoporotic mice model with a femoral fracture age dependent differences were found: bending stiffness, callus size, and callus tissue distribution were not altered in 5-month-old osteoporotic mice compared to non-osteoporotic mice. In 10-month-old osteoporotic mice however bending stiffness was significantly reduced and callus size was increased compared to non-osteoporotic mice, indicating delayed fracture healing, possibly explained by an increased osteoclast activity in the 10-month-old [10].

In rats, several studies showed that in the osteoporotic group the total callus, there was less bony callus and newly formed bone [11] as well as the bone mineral content and bone mineral density was reduced at the fracture site [12–16]. Other studies showed that the presence of osteoporosis had a negative impact on the quality and quantity of callus during early fracture healing [12,17] and biomechanical testing [11–13,16,18–22]. Another study performed in rats with a tibial bone defect showed that osteoporosis resulted in significantly less newly formed bone, a higher amount of granulation tissue and immature newly formed bone, compared to rats without osteoporosis [23]. Histological evaluation revealed a delay in the cellular differentiation processes of chondrocytes during fracture healing [12,13,18]. In ovariectomized rats with a femoral osteotomy, histological analyses showed less mature consolidation [21], significantly reduced bone volume was found at the gap [24], the gap contained more osteoclasts [24] and the gap was filled with scattered smaller bone trabeculae [24] compared to non-ovariectomized rats. But the microcomputer tomography (μ CT) showed no difference in consolidation [21]. However Gauo et al. [19] found no significant differences in bone microarchitecture on the micro CT between the osteoporotic and non-osteoporotic rats 12 weeks after fracture induction. Coa et al. [25] also did not find impaired callus formation or biomechanical strength.

Even in a larger animal model similar results were found. In fourteen sheep with a tibial shaft osteotomy osteoporosis resulted in impaired fracture healing with respect to callus formation, mineralization, and biomechanical properties [26].

Two studies showed that fracture healing in osteoporotic animals was also radiographically lagging behind [12,18], or described clear differences in union rate (59% osteoporotic group vs 89% in the control group) after 8 weeks [16]. One study found that the fracture was partly united compared to a clearly present fracture gap in osteoporotic animals at 4 weeks. However, after 12 weeks bone union was observed in both groups [19]. Kubo et al. [15] also showed no radiological

Table 1

Summary of the effect of osteoporosis on fracture healing in animal studies.

Osteoporosis	↓ callus/bone formation [11,17,23,24,26] ↓ bone mineral content [12–16,26] or density [12–17] ↓ biomechanical strength [9–13,16,18–21,26] Delay cellular differentiation/processes [9,12,13,15,16,18,21,24] Radiological delay [12,16,18] or no difference [15,19,25]
---------------------	---

↑ significant increased, ↓ significant decreased.

differences in femoral fracture healing between ovariectomized and non-ovariectomized rats. Another study in ovariectomized and non-ovariectomized rats did not show a clear impairment of radiological healing [25].

3.2. Effect of osteoporosis on fracture healing - clinical studies (Table 2)

No meta-analyses were found investigating the effect of osteoporosis on fracture healing. Five clinical studies, 3 prospective and 2 retrospective, were found investigating the effect of osteoporosis on fracture healing. Overall, two large databases identified osteoporosis as a risk factor for non-union while three other studies did not. One of those three studies however found a prolonged healing time in patients with osteoporosis.

In two large database studies osteoporosis was identified as a risk factor for non-union [27,28]. In one analysis of a national insurance database, 47,437 patients were included in 12 months with 56,492 fractures for which a non-union was registered in 2.5%. Sixty potential patient characteristics and co morbidities for non-union were assessed and osteoporosis was identified as a risk factor for non-union [27]. In an even larger database using patient-level health claims, 309,330 fractures in 18 bones with 15,249 non-unions (4.9%) were registered in 12 months. Again osteoporosis was identified as an influencing factor [28]. In a matched case-control study, on prospective gathered data, of 40 patients with fracture non-union and 80 patients without a fracture non-union a regression analysis was performed to investigate whether the presence of osteoporosis attributed to the non-union, but did not detect any correlation [29].

In a small study, 29 patients, aged >65 years, with a femoral shaft fracture and radiological evidence of osteoporosis based on the Singh index were retrospectively compared with 37 subjects, aged between 18 and 40 years, without radiological evidence of osteoporosis. A prolonged union time (19.38 ± 5.9 weeks vs 16.19 ± 5.07 weeks, $p = 0.02$) with more delayed unions (>24 weeks) was described (10/29 vs 4/37 $p = 0.03$) in the older group with osteoporosis. However, all fractures healed within 32 weeks [30]. Although patients with known metabolic disorders were excluded, no analysis to unknown metabolic disorders was performed nor correction was performed for age. A retrospective study on subcapital humerus fractures ($n = 311$) and distal radius fractures ($n = 150$) found a seemingly negative association, but no statistically significant evidence that osteoporosis was associated with delayed or non-union [31].

3.3. Effect of anti-osteoporosis medication on fracture healing - animal studies (Table 3)

A total of 41 studies were found describing the effect of anti-osteoporosis medication on fracture healing in both osteoporotic and non-osteoporotic animal models. The studies were subdivided based on the working mechanism of the drug (antiresorptive or anabolic), type of medication and whether the medication was studied in a non osteoporotic or osteoporotic animal model. Both male and female species were used for non-osteoporotic models, whereas only female species were used in the osteoporotic animal models. Overall, inconsistent effects on fracture healing in both non-osteoporotic and osteoporotic animal models were observed. Antiresorptive drugs, bisphosphonates in particular, resulted in delayed remodelling of callus in both models. Parathyroid hormone was related to improved fracture healing.

3.3.1. Antiresorptive medication

3.3.1.1. Bisphosphonates. In male non osteoporotic rats models increased callus volume [32], hard callus bone mineral content [33], histologically more advanced healing [34] and increased mechanical strength [33,35] were found after supplementation of bisphosphonates.

Table 2
Summary of the effect of osteoporosis on fracture healing in clinical studies.

Author	Study design	Fracture location	n (patients/control)	Effect	Bias
v Wunnik [29]	Prospective matched controlled	Various	120 (40/80)	No effect on incidence of non-union	Variety of fractures location Small number of patients
Zura [27]	Prospective cohort	Various	56,492 (1440/55,052)	↑ risk of non-union (multivariate analysis OR 1.423, Robust SE 0.108; $p < 0.001$)	Variety of fractures location Insurance database
Zura [28]	Inception cohort	Various	309,330 (15,249/294,081)	↑ risk of non-union (multivariate analysis OR 1.24, 95% CI (1.14–1.34))	Variety of fractures location Insurance database
Nikolaou [30]	Retrospective	Femoral shaft	66 (29/37)	↑ time to union (19.4 weeks vs 16.2 weeks, $p = 0.02$) and delayed union (10/29 vs 4/37 $p = 0.03$)	Selection/inclusion Small number of patients
Gorter [31]	Retrospective	Subcapital humerus and distal radius	455 (133/322)	No effect on incidence of non-union No clear effect on delayed or non-union	No correction for age Retrospective design Small number of patient in subgroup Outcome parameter

↑ significant increased, ↓ significant decreased.

Table 3
Summary of effect of osteoporosis treatment on fracture healing in animal studies.

Mechanism	Medication group	Non osteoporotic animal models	Osteoporotic animal models (female)
Antiresorptive	Bisphosphonates	Male ↑ callus formation [32,33,38] ↑ biomechanical strength [35] Histologically advanced healing [34]	Female ↑ bone mineral content/density [38] ↑ callus formation [39]
		No effect on biomechanical strength [36,38] No effect on radiological healing [34] No effect on incidence non-union [33,36] Delay remodelling [33,35,37]	↑ bone mineral content [25] ↑ callus formation [19,40,42] ↑ biomechanical strength [19,40,41] Histologically advanced healing [40] No effect on biomechanical strength [43] No effect on radiological healing [41] No effect on callus formation [43] No effect on incidence non-union [41]
		Male –	Female ↑ bone mineral content [38] ↑ biomechanical strength [38] ↑ newly formed bone [44]
Anabolic	Parathyroid hormone	Male ↑ bone mineral content [50,54]/density [49,54] ↑ callus formation [49–52] ↑ newly formed bone [32,33,39,50,53] ↑ biomechanical strength [49–51,53] Histological advanced healing [55] Improved radiological healing [49] Improved union rate [55] No effect on union rate [51]	Female No effect on callus formation [47] No effect on biomechanical strength [47] Delay remodelling [47] Female ↑ bone mineral content [38,56]/density [56] ↑ newly formed bone [38,57] ↑ biomechanical strength [38,56] Improved union rate [57]
		Male –	Female –
Dual effect	Strontium ranelate	Male No effect on fracture healing [68] No effect on radiological healing [68]	Female ↑ callus formation [38] ↑ bone mineral density [38] ↑ biomechanical strength [38] No effect on biomechanical strength [67]
		Male –	Female –
	RANK ligand inhibitor	Male ↑ biomechanical strength [35] Delay remodelling [35]	Female No effect on callus formation [47] No effect on biomechanical strength [47] Delay remodelling [47] Female ↑ bone mineral content [58,61]/density [61] ↑ callus formation [59] ↑ newly formed bone [61,63–66] ↑ biomechanical strength [59,60] Improved union rate [57] No effect on callus formation [58] No effect on radiological healing [58] ↑ callus formation [22,69–71] ↑ newly formed bone [69] ↑ bone mineral density [69,70] ↑ biomechanical strength [69,71] No effect on fracture healing [14]

↑ significant increased, ↓ significant decreased.

Table 4
Summary of effect of osteoporosis treatment on fracture healing in clinical studies.

Mechanism	Medication Group	Author	Study design	BMD	Fracture location	n (patients/control)	Drug initiation	Effect
Antiresorptive	Bisphosphonates	Li [72]	Meta-analysis	Mixed		2888		No effect on time to union or union rate
		Colon-Emeric C [74]	RCT	Mixed and unknown	Hip	2127 (1065/1062)	< 90 days vs placebo	No effect on incidence of delayed union or union rate
		Uchiyama [76]	RCT	Mixed		80 (40/40)	<4 d vs >4mo after surgery	No effect on time to union or union rate
		Kim [73]	RCT	Osteoporotic	Hip	90 (30/30/30)	<1wk vs > 1mo vs > 3mo	No effect on incidence of delayed union or union rate
		Gong [78]	RCT	Osteoporotic	Distal radius	50 (24/26)	2wk vs 3mo after surgery	No effect on time to union or union rate
		Vd Poest clement [75]	RCT	Osteoporotic	Distal radius	37 (18/19)	After 2-4wk vs placebo	No effect on time to union
		Duckworth [77]	RCT	Unknown	Distal radius	421 (215/206)	<2wks vs placebo	No effect on union rate
		Shoji [83]	Prospective controlled cohort	Mixed	Distal radius	33 (11/22)	Current vs no use	No effect on union rate
		Hayer [79]	Prospective cohort	Osteoporotic	Hip	43	< 1wk	No effect on time to union
		Koshy [86]	Prospective controlled cohort	Unknown	Distal radius	66 (33/33)	Current vs no use	No effect on time to union
		Rozental [85]	Retrospective	Mixed	Distal radius	196 (43/153)	Current vs no use	Significant increased healing time (55 days vs 49 days)
		Solomon [84]	Retrospective	Mixed	Humerus	891 (81/810)	After fracture vs no use	Significant increased risk on non union (OR2.37, 95% CI 1.13–4.96)
		Lim [80]	Retrospective	Osteoporotic	Hip	130 (29/101)	Current or previously vs no use	Significant increased risk of delayed union after 3 months (union rate after 3 months 21/29 Vs 91/101), no difference after 1 year
		Seo [82]	Retrospective	Osteoporotic	Proximal humerus	82 (34/48)	<2wks vs >3mo after surgery	No effect on time to union or union rate
		Cho [81]	Retrospective	Osteoporotic	Hip	284 (102/89/93)	1wk vs 1 month vs 3 months	No effect on time to union
	RANK ligand inhibitor	Adami [87]	RCT	Osteoporotic	Nonvertebral fractures	7808 (3902/3906)	Denosumab vs placebo	No effect on delayed and non union
Anabolic	Parathyroid hormone	Han [88]	Meta-analysis	Osteoporotic and unknown	Hip	607		Significant reduced time to union (OR–1.95; 95% CI: –3.23–0.68), no effect on union rate after 3 or 6 months.
		Hong [95]	Meta-analysis	Mixed and unknown		524		(–3.05, 95% CI –5.96 to –0.14) reduced time to union, no effect on union rate
		Peichl [96]	RCT	Osteoporotic	Pubic	65 (21/44)	100 µg PTH 1–84 vs control	Significant reduced time to union (7.8 weeks vs 12.6 weeks)
		Kanakaris [97]	RCT	Osteoporotic	Hip		vitDcalcium Vs vitD calcium & bisphosphonates Vs vitD calcium & teriparatide	Prematurely ended due to slow patient accrual
		Bhandari [93]	RCT	Unknown	Hip	159 (78/91)	20 µg teriparatide vs placebo	Prematurely ended due to slow patient accrual, but no difference radiological union rate
		Chesser [94]	RCT	Unknown	Hip	29 (15/14)	Teriparatide vs control	No difference in union rate
Aspenberg [99]	RCT	Unknown	Distal radius	102 (34/34/34)	20 µg vs 40 µg teriparatide vs placebo during 9 weeks	20 µg significant reduced time to union (7.4 weeks vs 9.1 weeks), however 40 µg did not		

(continued on next page)

Table 4 (continued)

Mechanism	Medication Group	Author	Study design	BMD	Fracture location	n (patients/control)	Drug initiation	Effect
		Almirol [98]	RCT	Unknown	Stress fracture leg	13 (6/7)	20 µg teriparatide vs placebo	No difference in radiographic fracture healing
		Huang [89]	Retrospective	Osteoporotic	Hip	189 (83/47/59)	vitD calcium Vs vitD calcium and teriparatide Vs previous on alendronate after fracture on vitD calcium and teriparatide	Significant reduced time to union (12.3 weeks vs 13.6 weeks), no effect on incidence of delayed union
		Huang [90]	Retrospective	Osteoporotic	Hip	73 (29/44)	20 µg teriparatide vs no	Significant reduced time to union (11.2 weeks vs 14.3 weeks), no effect on incidence of delayed- or non- union
		Kim [91]	Retrospective	Osteoporotic	Hip	112 (52/60)	20 µg teriparatide vs nothing	Significant reduced time to union (12.1 weeks vs 14.8 weeks), no effect on incidence of non union
		Kim [92]	Retrospective	Osteoporotic	Hip	96 (50/46)	Daily teriparatide vs nothing	No difference in time to union
Dual effect	Strontium ranelate	Scaglione [101]	RCT	Unknown	Distal radius	40 (20/20)	vitD calcium Vs vitD calcium and strontium ranelate	No effect on radiological follow-up

BMD Bone mineral density; RCT Randomized controlled trial.

Another study found no effect on mean elastic modulus and hardness of the callus tissue in male rats [36]. In male rat models delayed fracture healing [37] and remodelling [33,35,37] was found after supplementation of bisphosphonates, but also no effect on union rate was described. [33,36] Aydogan et al. [34] found no effect of on fracture healing in rats with a femur fracture in radiological follow-up. In female non osteoporotic rat models with a femoral fracture, treatment with bisphosphonates increased bone mineral content [38], bone mineral density [38] and callus volume [38] compared to wild type rats [38] and local application of bisphosphonates resulted in more callus formation [39].

Osteoporotic models – In rats with a tibial fracture, administration of zoledronic acid resulted in increased biomechanical strength, more callus as well as thicker and more mature bone trabeculae, and in both the zoledronic acid group and the control group there was complete healing [40]. Bisphosphonates in rats with a femoral fracture increased the mechanical strength of the callus [41] and hard callus bone mineral content [25]. Mice with a femoral osteotomy treated with alendronate showed an increase in newly formed bone at the defect site [42]. Local application of bisphosphonates at the fracture site in rats improved bone microarchitecture, mechanical character and resulted in more callus [19]. However, one study found that the administration of alendronate in osteoporotic rats with a metaphyseal tibial fracture did not influence the process of fracture healing quantitatively or qualitatively [43]. Despite the observed positive effects of bisphosphonates other studies in rats found suppressed callus remodelling [41], delayed remodelling [25] and suggested that continuous administration might be detrimental to bone repair [42].

3.3.1.2. Selective estrogen receptor modulator (SERM). In a comparative study of 60 non osteoporotic female mice the administration of raloxifen resulted in enhanced fracture healing and earlier complete bony bridging of the femoral osteotomy gap compared to mice not receiving raloxifen [44]. In non osteoporotic female rats, raloxifen treatment increased bone mineral content, bone mineral density and biomechanical properties significantly, even though no greater bone volume on CT scans compared to other treatment groups was observed. [38]

Osteoporotic models – In rat models the effect of raloxifen on peri-implant bone healing was investigated by Ramalho-Ferreira et al [45]. They showed improved fracture healing compared to osteoporotic rats

not receiving raloxifen and similar histological and biomechanical values compared to the non-osteoporotic rats. In rats with a metaphyseal tibial fracture raloxifen in combination with estrogen resulted in improved fracture healing with regard to callus formation [46]. On the other hand, no effect on callus formation or biomechanical properties was found by Cao et al. [25] in female rats and raloxifen was not found to be more inhibitory on the process of fracture healing due to inhibited resorption activity and reduced remodelling.

3.3.1.3. RANK ligand inhibitor. Non osteoporotic animal models – Ulrich-Vinther et al. [47] showed that OPG (natural decoy binding protein of RANKL) treatment did not influence callus formation or mechanical strength in female rats, however during the remodelling phase it impaired the normal remodelling and consolidation process. In a mouse model treatment with RANK-ligand inhibitor resulted in reduced bone resorption during fracture healing without being detrimental to fracture healing [48]. Gerstenfeld et al. [35] found an increased mechanical strength in male mice after treatment with denosumab, but showed delayed callus remodelling.

3.3.2. Anabolic medication

3.3.2.1. Parathyroid hormone. Non osteoporotic male animal models – Treatment with a PTH receptor agonist resulted in increased callus osteogenesis, improved fracture bridging, greater bony callus size and density, improved biomechanical stability and more callus on radiological follow-up in male rats with a femoral fracture [49]. Also in other animal fracture studies PTH supplementation resulted in complete consolidation [38], enhanced biomechanical strength [38,50,51], bone mineral content [38,50], denser callus [52] and more callus [50,51] or newly formed bone [38,50]. In rats with type 2 diabetes and a femoral fracture the administration of PTH resulted in increased bone formation, mineralization and mechanical strength [53]. In rats with a large sized osteotomy in the femur local and systemic PTH was applied and resulted in higher bone mineral density and bone mineral content at the osteotomy site compared to rats without treatment [54]. With regards to fracture union, in a rat model with an open or closed femoral osteotomy the treatment with PTH did not result in an increased union rate [51]. In a femoral atrophic non-union model in mice, treatment with PTH showed higher rates of bony union and reduced mean gap size with cortical

bridging with mature bone and relatively little callus on histological analysis [55].

Non osteoporotic female animal models – Also in female animal fracture studies PTH supplementation resulted in complete consolidation [38], enhanced biomechanical strength [56], bone mineral content [56], increased BMD [56] and Nozaka et al [57] found in rats with a proximal tibial osteotomy increased cancellous bone formation and improved union rate.

Osteoporotic animal models – In ovariectomized rats Ellegaard et al. [58] showed that treatment with parathyroid hormone (PTH) resulted in a non-significantly increased amount of callus after 4, 6 weeks and no difference after 8 weeks. Also PTH supplementation resulted in enhanced biomechanical strength [59,60], bone mineral content [58,61], increased BMD [58,61] and more callus [58,59] or newly formed bone [60–62]. In rats, the administration of parathyroid hormone improved the differentiation and proliferation of hypertrophic chondrocytes [63], and newly formed trabecular bone was increased [63] as well as the cancellous bone formation [57,63]. The finding that PTH enhances bone formation was supported by other studies in which also local beta-tricalcium phosphate was applied at the defect site [64,65]. A combination of teriparatide and anti-RANKL monoclonal antibody in mice resulted in accelerated regeneration of cancellous bone during fracture, however no effect was found on cortical bone regeneration or cortical bone thickness [66]. In rats with a cancellous bone osteotomy of the tibia the administration of parathyroid hormone improved union rate [57].

3.3.3. Antiresorptive and anabolic medication

3.3.3.1. *Strontium ranelate*. Non osteoporotic animal models – Administration of strontium ranelate in a female fracture animal model resulted in increased bone formation, bone mineral density, higher mechanical strength and improved callus formation [38]. One study found a positive effect on callus volume and bone mineral content after 3 weeks but no effect after 8 weeks and no effect on maximum load or stiffness at the fracture site in female rats [67]. Also in male rats, Cebesoy et al. [68] found no beneficial effects of strontium ranelate on radiological or histopathological fracture healing.

Osteoporotic animal models – Administration of strontium ranelate in several fracture or osteotomy animal models resulted in increased bone formation [22,69], bone mineral density [22,69,70], higher mechanical strength [22,69,71] and fracture stiffness [71], improved callus formation [69–71]. However, one study showed that administration of strontium ranelate with insulin compared to only insulin in ovariectomized diabetic rats did not display a significant advantage regarding fracture healing [14].

3.4. Effect of anti-osteoporosis medication on fracture healing - clinical studies (Table 4)

A total 26 clinical studies and 3 meta-analyses were found describing the effect of anti-osteoporosis medication on fracture healing. The studies were subdivided based on their effect (antiresorptive or anabolic), medication group and whether the medication was supplemented in a osteoporotic or non-osteoporotic patients. Overall, no clearly positive nor negative effect could be found of antiresorptive medication on fracture healing. With regards to the anabolic medication, recombinant parathyroid hormone decreased time to union in several studies without an effect on delayed or non union rates. One study was found on strontium ranelate, which showed no effect.

3.4.1. Antiresorptive medication

3.4.1.1. *Bisphosphonates*. A meta-analysis of the effect of bisphosphonates on fracture healing of 10 RCTs including 2888 osteoporotic and

non-osteoporotic fracture patients was performed by Li et al. [72]. No effect on fracture healing time nor on delayed or non-union was found [72]. This meta-analysis included all our identified RCTs [73–76] except for the studies performed by Duckworth et al. [77] and Gong et al. [78]. Their RCTs on the effect of bisphosphonates on the healing of a distal radius fracture also showed no difference in mean time to radiographic union [78] or union rate [77,78].

Osteoporotic fracture patients – Gong et al. [78] investigated the effect of bisphosphonates on the healing of a distal radius fracture in a RCT and found no difference in mean time to radiographic union or union rate. In a prospective cohort study performed with 43 hip fracture patients a single dose of zoledronic acid did not affect radiological fracture union [79]. However, a retrospective analysis among 130 patients with a hip fracture showed that the preoperative use of bisphosphonate ($n = 29$) related to less fracture union after 3 months compared to no bisphosphonate use (72.4% vs 90.1%), but no differences in union rates were found after one year [80]. Cho et al. [81] retrospectively investigated in 284 hip fracture patients whether administration of bisphosphonates after 1 week, 1 month or 3 months influenced fracture healing time. They found no difference in time to union and no cases of non union. In a retrospective study among 82 patients with a operated proximal humerus fracture early initiation of bisphosphonates (<2 weeks) versus late initiation (> 3 months) was investigated, and no difference in union time (6.3 vs 6.6 weeks) or union rate was found [82]. Overall, only one retrospective study found an increased risk on delayed unions based on a difference in union rates after 3 months, without a difference after one year [80]. On the other hand 3 RCTs, one prospective trial and 2 retrospective trials found no effect (Table 4).

Osteoporotic and non osteoporotic fracture patients – One prospective study included 33 patients with a distal radius fracture and found no effect on union rate or function [83]. In a nested case-control study from a large insurance database, 81 patients who underwent an operation for fracture non-union of a humeral fracture were compared with 810 patients without a humeral fracture non union. A multivariate conditional logistic regression analysis showed that post-fracture bisphosphonate use resulted in an increased risk of non-union (RR = 2.37, 95% CI 1.13–4.96), but pre-fracture use did not (RR = 0.84, 95% CI 0.19–3.74) [84]. In patients without previous fractures or osteoporosis also no effect was found. Although not considered clinically relevant by the authors, one retrospective study on distal radius fractures found an increased healing time (55 days vs 49 days) [85].

Osteoporosis status unknown – The randomized controlled trial by Duckworth et al. [77] found no effect of bisphosphonates on union rate in the healing of a distal radius fracture. Also a retrospective study in patients with a distal radius showed no effect of bisphosphonate on the occurrence of radiological or clinical delayed union [86].

3.4.1.2. *RANK ligand inhibitor*. In the Freedom trial almost 8000 postmenopausal women >60 years with osteoporosis were randomized to receive 60 mg of denosumab every six months for three years or a placebo. In a sub-analysis of fracture healing among 851 non-vertebral fracture patients (386 in the denosumab group and 465 in the placebo group), delayed union was only reported in two patients (0.5%) in the denosumab group and five patients (1.1%) in the placebo group. No non-unions and one non-union were reported in the denosumab group and placebo group respectively [87].

3.4.2. Anabolic medication

3.4.2.1. *Recombinant parathyroid hormone*. A recent meta-analysis on the effect of teriparatide on fracture healing in hip fracture patient analysed all 2 RCTs and 4 retrospective studies on hip fracture patients that we identified. [88] Teriparatide was found not to affect union rate, due to study heterogeneity and various sources of biases the limited

evidence found did not support the hypothesis that teriparatide improves fracture healing in hip fractures [88]. They included four studies performed in an osteoporotic fracture population [89–92] and two with an unknown osteoporosis status [93,94]. Another meta-analysis in 2019 investigated the efficacy and safety of r-PTH in fracture healing [95]. This meta-analysis included the eight RCTs that were identified in the present search; three studies were performed in an osteoporotic fracture population [89,96,97], in four studies osteoporosis status was unknown [93,94,98,99] and one including both osteoporotic and non osteoporotic patients [100]. Three studies found reduced radiographic time to fracture healing in subjects using teriparatide, although heterogeneity within the studies was high. Four studies found no difference in union rate, again with a high heterogeneity [95]. Remarkable, two or the eight performed RCTs had significant problems with patient recruitment and completion of follow up [93,97]. Of these, only Bhandari et al. [93] analysed their data but were underpowered with 159 patients showing no difference regarding radiographic fracture healing. Among the six remaining RCT's, one was a pilot study among 29 hip fracture patients and found no difference in union rate [94]. Of the remaining five RCTs, only one found a positive effect of recombinant parathyroid hormone. In this randomized study with 65 patients with a pubic bone fracture, daily supplementation of recombinant parathyroid hormone 1–84 reduced the mean time to fracture healing compared to no medication (7.8 weeks vs 12.6 weeks, $p < 0.001$). After eight weeks all fractures ($n = 21$) in the treatment group were healed and only 4/44 fractures in the control group were healed ($p < 0.001$) [96].

Four remaining retrospective studies in hip fracture patients, were also analysed in the meta-analysis of Han et al. [88]. Three out of four found a reduced time to union in the group of patients treated with teriparatide [89–91], while one study did not find a difference in fracture healing time [92]. Despite the reduced time to union, none of these three studies found a difference in the occurrence of delayed or non-unions [89–91].

Concerning osteoporotic fracture patients, one RCT and 3 retrospective studies found reduced times to fracture union without an effect on union rate. One retrospective study found no effect.

3.4.3. Antiresorptive and anabolic medication

3.4.3.1. Strontium ranelate. One study evaluated the effect of strontium in fracture healing. In a RCT, 40 nonoperatively treated distal radius fracture patients with an unknown osteoporosis status received either supplementation with vitamin D and calcium or supplementation with vitamin D, calcium and strontium ranelate. No differences in radiological follow-up, clinical evaluation, and ultrasonography of the callus were found between the two groups [101].

4. Discussion

The aim of this systematic review was to elucidate the relationship between osteoporosis and its treatment on fracture healing. In animal studies osteoporosis negatively influenced fracture healing in the majority of studies, with regard to cellular processes, callus formation, mineralization and biomechanical strength. In human studies this evidence was not convincing, although there seemed to be a tendency towards a negative influence of osteoporosis on fracture healing with prolonged healing time and increased risk on non-union. Inconsistent effects of anti-osteoporosis medication on fracture healing in both non-osteoporotic and osteoporotic animal models were observed. Anti-resorptive medication, bisphosphonates in particular, resulted in delayed remodelling of callus in both models. Teriparatide was found to enhance fracture healing in animal models. In clinical studies however, no clear negative effect of bisphosphonates were found on time to union and on increased delayed or non union rates. Recombinant parathyroid hormone did seem to decrease time to union without an effect on

delayed or non union rates.

The effect of osteoporosis on fracture healing in animal models was primarily investigated in rats and mice. The majority of the results suggested a negative biomechanical or histopathological influence of osteoporosis on fracture healing [9–19,21,23,24,26], whereas only three studies found radiological evidence of delayed union [12,16,18]. This may suggest that local signs of impaired or lagging fracture healing cannot always be radiologically objectivated, which has to be taken into mind while interpret the results. A potential limitation of some studies is the use of animal models with induced osteoporosis. Animals must receive treatments in order to produce a state of low bone mineral density or to become osteoporotic. All studies used ovariectomized animals to create an animal osteoporosis model, except for one study, which used a genetically induced osteoporosis model. [10] In six studies complementary diet was used after ovariectomy [13–15,22,24,26]. Since this is not a natural process in animals, interference with fracture healing could occur. Nevertheless, these models are standardly used for basic research on human biological processes. Additional human factors in fracture healing do not impair these models in such a way that results from animal based studies on osteoporosis have become meaningless. Another point of interest is the lack of a uniform definition of osteoporosis in these animals models. In 11 studies the BMD was checked with a DEXA-scan [11,13,15,16,18,21,22] or micro-CT [9,24–26], before the experiments to investigate the effect of osteoporosis on fracture healing were started. One study defined osteoporosis as a BMD ≥ 2.5 standard deviation (SD) lower than the BMD of the control group [13], whereas another study used a definition in which the BMD should be significantly lower than that of the control group [11]. However, the majority of the studies did not define animal osteoporosis and only described a significant lower BMD in the ovariectomized population [9,12,15,16,18,21] compared to the control group by, or diagnosed osteoporosis by the means of a DEXA without providing further details [22]. In case of micro-CT no clear definition of osteoporosis was defined either, but changes of bone architecture were described used to identify osteoporosis; less trabecular bone, disorganized trabecular architecture, expanded marrow cavities and thinning cortical bone [9].

Only five studies investigating the influence of osteoporosis on fracture healing in humans were found. Nikolaou et al. [30] found an increased time to union and delayed union rates, but classified osteoporosis patients based on X-rays (Singh index) and not on DEXA-scan or diagnosed by an endocrinologist. Two large database studies which found a negative effect of osteoporosis [27,28] might show the power of big data analyses, since the three smaller studies found no clear effect on the incidence of non-union possibly due to lack of statistical power. However, caution is warranted in interpreting these results, as stated by the authors. These large databases were based on claims by patients, often the codes were imprecise, patients were not followed prospectively for a specific outcome and also data was missing. Zura et al. [28] performed the only clinical study that included the use of anti-osteoporosis medication as a variable in their analysis and indeed identified this as a risk factor. The study by Gorter et al. [31] was retrospective, in which only in a small number of patients radiological follow up was available and the possible effect of osteoporosis treatment was not taken into account. More prospective studies like that of Van Wunnik et al. [29] are needed in order to elucidate whether osteoporosis has a negative influence on fracture healing.

In both the non-osteoporotic and osteoporotic animal models, anti-osteoporosis medication was found either to improve or not to influence fracture healing. Also no convincing difference was found between studies performed in male versus female non-osteoporotic animal models. In order to achieve full fracture healing, resorption of the newly formed callus occurs during the remodelling phase. As might be expected some studies on antiresorptive medication, which counteracts resorption, found a negative effect on the remodelling phase of fracture healing [25,33,35,41,42,47]. There was however no evidence that this negatively influenced the healing process or biomechanical properties of

the fracture. Parathyroid hormone showed in both animal models predominantly a positive effect on callus formation, bone mineral content, biomechanical strength and improved union rates in several studies.

Compared to clinical studies on osteoporosis, remarkably more clinical data was available on the effect of anti-osteoporosis medication on fracture healing. Although the studies included typical fragility and osteoporotic fractures, not every study included only patients with a T score < -2.5 and in some studies the information on the BMD was missing at all. None of the studies was performed in non-osteoporotic patients only. Studies on bisphosphonates were predominantly performed in hip and distal radius fracture patients and no effect on fracture healing was found. Especially no clear evidence of delayed union was reported, which might be expected based on the results found in animal models. In case of parathyroid, predominantly hip fracture patients were studied, and the results were more in line with the data found in animal models. Parathyroid hormone seems to improve time to union, however no clear effect on delayed union or non union rates was found. Both meta-analyses showed a high heterogeneity in the included studies due to differences in study design, different BMD groups and fracture locations. Parathyroid hormone supplementation has also been investigated in case of non-union treatment. A recent review concluded that teriparatide could be effective in the treatment of non-unions, when general principles of non-union and infections were dealt with [102]. On the other hand, the positive effects of treatment with teriparatide in order to improve fracture healing in atypical fractures have not been established. [102–108] Only six RCTs investigated medication versus placebo [74,75,77,87,93,98], in other RCTs patients were randomized between early initiation versus late initiation of medication [73,76,109] or patients were randomized between receiving the medication or not [96,97,100,101]. In order to unambiguously establish the effect of the treatment, a comparison with a placebo should be considered the preferred design. Nevertheless, in the three RCTs comparing early versus late initiation, late initiation was thus late that most of the fracture had already healed. The effect of the medication on fracture healing could be neglected and these patients could be considered as a control group without treatment. The meta-analyses of Han et al. [88] and Li et al. [72] were well performed, whereas the meta-analysis of Hong et al. [95] included also a retrospective study while a randomized study design was an inclusion criterion. Unfortunately for the statistical power, a large number of RCTs and even retrospective studies were performed in a small number of patients despite the fact that an osteoporotic fracture is common. Distal radius fractures have a high union rate and hip fracture patients are often lost to follow-up in prospective studies as shown by Bhandari et al. [93] and Kanakaris et al. [97]. Futures studies should preferably also include large osteoporotic populations of patients with fractures that are known to be associated with a relatively high non-union rate.

Our aim was to provide a systematic review of the current literature in an attempt to elucidate the role of osteoporosis and osteoporosis treatment as potential risk factors for impaired fracture healing in animal and clinical studies. Due to the considerable number of agents that have been studied in different species and patient populations using different study designs, fracture locations and outcome parameters, a meta-analysis was considered not feasible.

In general, one might question the clinical relevance of the shorter radiological union times found in several studies on recombinant parathyroid hormone supplementation [88–91,95,96,99]. Additional data about the clinical and patient-reported outcomes should be provided in order to assess the relevance of this radiological outcome. If a shorter time to radiological union does not influence clinical and patient-reported outcomes, nor does it influence fracture treatment or result in decreased risk on a delayed- or non-union, the clinical relevance of this finding could be deliberated.

In conclusion, animal studies suggest that osteoporosis negatively influences fracture healing. Clinical studies also show a possible negative tendency, but the evidence is still not convincing. In animal models

anti-resorptive medication delayed fracture remodelling and teriparatide was related to improved fracture healing, but no clear negative influence of anti-osteoporosis medication on fracture healing could be determined in fracture patients. Recombinant parathyroid hormone did seem to decrease time to union without an effect on delayed or non union rates. Based on this evidence, clinicians should not treat fractures differently in case of osteoporosis and initiate or continue anti-osteoporotic medication in osteoporotic fracture patients without restraint.

CRediT authorship contribution statement

Gorter; Conceptualization, Methodology, Investigation, Data Curation, Writing - Original Draft. **Reinders**; Data Curation, Writing - Review & Editing. **Krijnen**; Conceptualization, Writing - Review & Editing. **Appelman-Dijkstra**; Writing - Review & Editing. **Schipper**; Conceptualization, Writing - Review & Editing, Supervision.

Declaration of competing interest

None.

References

- 1 Schindeler, A., McDonald, M.M., Bokko, P., Little, D.G., 2008. Bone remodeling during fracture repair: the cellular picture. *Semin. Cell Dev. Biol.* 19 (5), 459–466.
- 2 Tsiridis, E., Upadhyay, N., Giannoudis, P., 2007. Molecular aspects of fracture healing: which are the important molecules? *Injury* 38 (Suppl 1), S11–S25.
- 3 Marsell, R., Einhorn, T.A., 2011. The biology of fracture healing. *Injury* 42 (6), 551–555.
- 4 Giannoudis, P.V., Einhorn, T.A., Marsh, D., 2007. Fracture healing: the diamond concept. *Injury* 38 (Suppl 4), S3–S6.
- 5 Copuroglu, C., Calori, G.M., Giannoudis, P.V., 2013. Fracture non-union: who is at risk? *Injury* 44 (11), 1379–1382.
- 6 Giannoudis, P., Tzioupis, C., Almaliki, T., Buckley, R., 2007. Fracture healing in osteoporotic fractures: is it really different? A basic science perspective. *Injury* 38 (SUPPL. 1), S90–S99.
- 7 Scientific Advisory Board of the European Society for C, Economic Aspects of O, the Committees of Scientific A, National Societies of the International Osteoporosis F, Kanis, J.A., Cooper, C., Rizzoli, R., Reginster, J.Y., 2019. European guidance for the diagnosis and management of osteoporosis in postmenopausal women. *Osteoporos. Int.* 30 (1), 3–44.
- 8 Yaacobi, E., Sanchez, D., Maniar, H., Horwitz, D.S., 2017. Surgical treatment of osteoporotic fractures: an update on the principles of management. *Injury* 48 (Suppl 7), S34–s40.
- 9 He, Y.X., Zhang, G., Pan, X.H., Liu, Z., Zheng, L.Z., Chan, C.W., Lee, K.M., Cao, Y.P., Li, G., Wei, L., et al., 2011. Impaired bone healing pattern in mice with ovariectomy-induced osteoporosis: a drill-hole defect model. *Bone* 48 (6), 1388–1400.
- 10 Histing, T., Kuntz, S., Stenger, D., Scheuer, C., Garcia, P., Holstein, J.H., Klein, M., Pohlemann, T., Menger, M.D., 2013. Delayed fracture healing in aged senescence-accelerated P6 mice. *J. Investig. Surg.* 26 (1), 30–35.
- 11 Hao, Y.J., Zhang, G., Wang, Y.S., Qin, L., Hung, W.Y., Leung, K., Pei, F.X., 2007. Changes of microstructure and mineralized tissue in the middle and late phase of osteoporotic fracture healing in rats. *Bone* 41 (4), 631–638.
- 12 Oliver, R.A., Yu, Y., Yee, G., Low, A.K., Diwan, A.D., Walsh, W.R., 2013. Poor histological healing of a femoral fracture following 12 months of oestrogen deficiency in rats. *Osteoporos. Int.* 24 (10), 2581–2589.
- 13 Namkung-Matthai, H., Appleyard, R., Jansen, J., Hao Lin, J., Maastricht, S., Swain, M., Mason, R.S., Murrell, G.A., Diwan, A.D., Diamond, T., 2001. Osteoporosis influences the early period of fracture healing in a rat osteoporotic model. *Bone* 28 (1), 80–86.
- 14 Cao, G.L., Tian, F.M., Liu, G.Y., Song, H.P., Yuan, L.L., Geng, L.D., Bei, M.J., Zheng, Z.Y., Zhang, L., 2018. Strontium ranelate combined with insulin is as beneficial as insulin alone in treatment of fracture healing in ovariectomized diabetic rats. *Med. Sci. Monit.* 24, 6525–6536.
- 15 Kubo, T., Shiga, T., Hashimoto, J., Yoshioka, M., Honjo, H., Urabe, M., Kitajima, I., Semba, I., Hirasawa, Y., 1999. Osteoporosis influences the late period of fracture healing in a rat model prepared by ovariectomy and low calcium diet. *J. Steroid Biochem. Mol. Biol.* 68 (5–6), 197–202.
- 16 McCann, R.M., Colleary, G., Geddis, C., Clarke, S.A., Jordan, G.R., Dickson, G.R., Marsh, D., 2008. Effect of osteoporosis on bone mineral density and fracture repair in a rat femoral fracture model. *J. Orthop. Res.* 26 (3), 384–393.
- 17 Xu, S.W., Yu, R., Zhao, G.F., Wang, J.W., 2003. Early period of fracture healing in ovariectomized rats. *Chin. J. Traumatol.* 6 (3), 160–166.
- 18 Wong, R.M., Thormann, U., Choy, M.H., Chim, Y.N., Li, M.C., Wang, J.Y., Leung, K.S., Cheng, J.C., Alt, V., Chow, S.K., et al., 2019. A metaphyseal fracture rat model for mechanistic studies of osteoporotic bone healing. *Eur. Cells Mater.* 37, 420–430.

- 19 Guo, J., Zhang, Q., Li, J., Liu, Y., Hou, Z., Chen, W., Jin, L., Tian, Y., Ju, L., Liu, B., 2017. Local application of an ibandronate/collagen sponge improves femoral fracture healing in ovariectomized rats. *PLoS ONE* 12 (11), e0187683 no pagination.
- 20 Wang, J.W., Li, W., Xu, S.W., Yang, D.S., Wang, Y., Lin, M., Zhao, G.F., 2005. Osteoporosis influences the middle and late periods of fracture healing in a rat osteoporotic model. *Chin. J. Traumatol.* 8 (2), 111–116.
- 21 Thormann, U., El Khawassna, T., Ray, S., Duerselen, L., Kampschulte, M., Lips, K., von Dewitz, H., Heinemann, S., Heiss, C., Szalay, G., et al., 2014. Differences of bone healing in metaphyseal defect fractures between osteoporotic and physiological bone in rats. *Injury* 45 (3), 487–493.
- 22 Habermann, B., Kafchitsas, K., Olender, G., Augat, P., Kurth, A., 2010. Strontium ranelate enhances callus strength more than PTH 1–34 in an osteoporotic rat model of fracture healing. *Calcif. Tissue Int.* 86 (1), 82–89.
- 23 Kido, H.W., Bossini, P.S., Tim, C.R., Parizotto, N.A., da Cunha, A.F., Malavazi, I., Renno, A.C., 2014. Evaluation of the bone healing process in an experimental tibial bone defect model in ovariectomized rats. *Aging Clin. Exp. Res.* 26 (5), 473–481.
- 24 Tatehara, S., Miyamoto, Y., Takechi, M., Momota, Y., Yuasa, T., 2011. Osteoporosis influences the early period of the healing after distraction osteogenesis in a rat osteoporotic model. *J. Cranio-Maxillofac. Surg.* 39 (1), 2–9.
- 25 Cao, Y., Mori, S., Mashiba, T., Westmore, M.S., Ma, L., Sato, M., Akiyama, T., Shi, L., Komatsubara, S., Miyamoto, K., et al., 2002. Raloxifene, estrogen, and alendronate affect the processes of fracture repair differently in ovariectomized rats. *J. Bone Miner. Res. Off. J. Am. Soc. Bone Miner. Res.* 17 (12), 2237–2246.
- 26 Lill, C.A., Hessel, J., Schlegel, U., Eckhardt, C., Goldhahn, J., Schneider, E., 2003. Biomechanical evaluation of healing in a non-critical defect in a large animal model of osteoporosis. *J. Orthop. Res.* 21 (5), 836–842.
- 27 Zura, R., Braid-Forbes, M.J., Jeray, K., Mehta, S., Einhorn, T.A., Watson, J.T., Della Rocca, G.J., Forbes, K., Steen, R.G., 2017. Bone fracture nonunion rate decreases with increasing age: a prospective inception cohort study. *Bone* 95, 26–32.
- 28 Zura, R., Xiong, Z., Einhorn, T., Watson, J.T., Ostrum, R.F., Prayson, M.J., Della Rocca, G.J., Mehta, S., McKinley, T., Wang, Z., et al., 2016. Epidemiology of fracture nonunion in 18 human bones. *JAMA Surg.* 151, e162775 no pagination.
- 29 van Wunnik, B.P., Weijers, P.H., van Helden, S.H., Brink, P.R., Poeze, M., 2011. Osteoporosis is not a risk factor for the development of nonunion: a cohort nested case-control study. *Injury* 42 (12), 1491–1494.
- 30 Nikolou, V.S., Efsthopoulos, N., Kontakis, G., Kanakaris, N.K., Giannoudis, P.V., 2009. The influence of osteoporosis in femoral fracture healing time. *Injury* 40 (6), 663–668.
- 31 Gorter, E.A., Gerretsen, B.M., Krijnen, P., Appelman-Dijkstra, N.M., Schipper, I.B., 2020. Does osteoporosis affect the healing of subcapital humerus and distal radius fractures? *J. Orthop.* 22, 237–241.
- 32 Murphy, C.M., Schindeler, A., Cantrill, L.C., Mikulec, K., Peacock, L., Little, D.G., 2015. PTH(1–34) treatment increases bisphosphonate turnover in fracture repair in rats. *J. Bone Miner. Res. Off. J. Am. Soc. Bone Miner. Res.* 30 (6), 1022–1029.
- 33 McDonald, M.M., Dulai, S., Godfrey, C., Amanat, N., Szynda, T., Little, D.G., 2008. Bolus or weekly zoledronic acid administration does not delay endochondral fracture repair but weekly dosing enhances delays in hard callus remodeling. *Bone* 43 (4), 653–662.
- 34 Aydogan, N.H., Ozel, I., Iltar, S., Kara, T., Ozmeric, A., Alemdaroglu, K.B., 2016. The effect of vitamin D and bisphosphonate on fracture healing: an experimental study. *J. Clin. Orthop. Trauma* 7 (2), 90–94.
- 35 Gerstenfeld, L.C., Sacks, D.J., Pelis, M., Mason, Z.D., Graves, D.T., Barrero, M., Ominsky, M.S., Kostenuik, P.J., Morgan, E.F., Einhorn, T.A., 2009. Comparison of effects of the bisphosphonate alendronate versus the RANKL inhibitor denosumab on murine fracture healing. *Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research* 24 (2), 196–208.
- 36 Amanat, N., He, L.H., Swain, M.V., Little, D.G., 2008. The effect of zoledronic acid on the intrinsic material properties of healing bone: an indentation study. *Med. Eng. Phys.* 30 (7), 843–847.
- 37 Baima Filho, F.A.S., Mendonca, P.G., Silva, G.E.B., Santos, O.J.D., Garcia, J.B.S., Cartagenes, M., 2020. The analysis of alendronate action in bone fracture healing in rats. *J. Clin. Orthop. Trauma* 11 (Suppl 5), S856–S860.
- 38 Leiblein, M., Henrich, D., Fervers, F., Konradowitz, K., Marzi, I., Seebach, C., 2020. Do antiosteoporotic drugs improve bone regeneration in vivo? *Eur. J. Trauma Emerg. Surg.* 46 (2), 287–299.
- 39 Menzendorf, L., Weuster, M., Kluter, T., Bruggemann, S., Behrendt, P., Fichten-Oestern, S., Varoga, D., Seekamp, A., Purcz, N., Glueer, C.C., et al., 2016. Local pamidronate influences fracture healing in a rodent femur fracture model: an experimental study. *BMC Musculoskelet. Disord.* 17 (1), 255 no pagination.
- 40 Turker, M., Aslan, A., Cirpar, M., Kochai, A., Tulmac, O.B., Balci, M., 2016. Histological and biomechanical effects of zoledronate on fracture healing in an osteoporotic rat tibia model. *Joint Dis. Rel. Surg.* 27 (1), 9–15.
- 41 Hao, Y., Wang, X., Wang, L., Lu, Y., Mao, Z., Ge, S., Dai, K., 2015. Zoledronic acid suppresses callus remodeling but enhances callus strength in an osteoporotic rat model of fracture healing. *Bone* 81, 702–711.
- 42 Hauser, M., Siegrist, M., Keller, I., Hofstetter, W., 2018. Healing of fractures in osteoporotic bones in mice treated with bisphosphonates - a transcriptome analysis. *Bone* 112, 107–119.
- 43 Kolios, L., Hoerster, A.K., Sehmisch, S., Malcherek, M.C., Rack, T., Tezval, M., Seidlova-Wuttke, D., Wuttke, W., Stuermer, K.M., Stuermer, E.K., 2010. Do estrogen and alendronate improve metaphyseal fracture healing when applied as osteoporosis prophylaxis? *Calcif. Tissue Int.* 86 (1), 23–32.
- 44 Spiro, A.S., Khadem, S., Jeschke, A., Marshall, R.P., Pogoda, P., Ignatius, A., Amling, M., Beil, F.T., 2013. The SERM raloxifene improves diaphyseal fracture healing in mice. *J. Bone Miner. Metab.* 31 (6), 629–636.
- 45 Ramalho-Ferreira, G., Faverani, L.P., Prado, F.B., Garcia, I.R., Okamoto, R., 2015. Raloxifene enhances peri-implant bone healing in osteoporotic rats. *Int. J. Oral Maxillofac. Surg.* 44 (6), 798–805.
- 46 Stuermer, E.K., Sehmisch, S., Rack, T., Wenda, E., Seidlova-Wuttke, D., Tezval, M., Wuttke, W., Frosch, K.H., Stuermer, K.M., 2010. Estrogen and raloxifene improve metaphyseal fracture healing in the early phase of osteoporosis. a new fracture-healing model at the tibia in rat. *Langenbeck's Arch. Surg.* 395 (2), 163–172.
- 47 Ulrich-Vinther, M., Andreassen, T.T., 2005. Osteoprotegerin treatment impairs remodeling and apparent material properties of callus tissue without influencing structural fracture strength. *Calcif. Tissue Int.* 76 (4), 280–286.
- 48 Flick, L.M., Weaver, J.M., Ulrich-Vinther, M., Abuzzahab, F., Zhang, X., Dougall, W.C., Anderson, D., O'Keefe, R.J., Schwarz, E.M., 2003. Effects of receptor activator of NFkappaB (RANK) signaling blockade on fracture healing. *J. Orthop. Res.* 21 (4), 676–684.
- 49 Lanske, B., Chandler, H., Pierce, A., Brown, J., Ominsky, M., Kostenuik, P., Hattersley, G., 2019. Abaloparatide, a PTH receptor agonist with homology to PTHrP, enhances callus bridging and biomechanical properties in rats with femoral fracture. *J. Orthop. Res.* 37 (4), 812–820.
- 50 Miltrey, A., Wieskoetter, B., Hinze, D., Grueneweller, N., Stange, R., Pap, T., Raschke, M., Garcia, P., 2017. Dose-dependent effect of parathyroid hormone on fracture healing and bone formation in mice. *J. Surg. Res.* 220, 327–335.
- 51 Tagil, M., McDonald, M.M., Morse, A., Peacock, L., Mikulec, K., Amanat, N., Godfrey, C., Little, D.G., 2010. Intermittent PTH(1–34) does not increase union rates in open rat femoral fractures and exhibits attenuated anabolic effects compared to closed fractures. *Bone* 46 (3), 852–859.
- 52 Bernhardtsson, M., Aspenberg, P., 2018. Abaloparatide versus teriparatide: a head to head comparison of effects on fracture healing in mouse models. *Acta Orthop.* 89 (6), 674–677.
- 53 Alder, K.D., White, A.H.A., Chung, Y.H., Lee, I., Back, J., Kwon, H.K., Cahill, S.V., Hao, Z., Li, L., Chen, F., et al., 2020. Systemic parathyroid hormone enhances fracture healing in multiple murine models of type 2 diabetes mellitus. *JBM R Plus* 4 (5), 1–12 e10359.
- 54 Chen, H., Frankenburg, E.P., Goldstein, S.A., McCauley, L.K., 2003. Combination of local and systemic parathyroid hormone enhances bone regeneration. *Clin. Orthop. Relat. Res.* 416, 291–302.
- 55 Lin, E.A., Liu, C.J., Monroy, A., Khurana, S., Egol, K.A., 2012. Prevention of atrophic nonunion by the systemic administration of parathyroid hormone (PTH 1–34) in an experimental animal model. *J. Orthop. Trauma* 26 (12), 719–723.
- 56 Alkhiary, Y.M., Gerstenfeld, L.C., Krall, E., Westmore, M., Sato, M., Mitlak, B.H., Einhorn, T.A., 2005. Enhancement of experimental fracture-healing by systemic administration of recombinant human parathyroid hormone (PTH 1–34). *J. Bone Joint Surg.* 87 (4), 731–741.
- 57 Nozaka, K., Miyakoshi, N., Kasukawa, Y., Maekawa, S., Noguchi, H., Shimada, Y., 2008. Intermittent administration of human parathyroid hormone enhances bone formation and union at the site of cancellous bone osteotomy in normal and ovariectomized rats. *Bone* 42 (1), 90–97.
- 58 Ellegaard, M., Kringelbach, T., Syberg, S., Petersen, S., Beck Jensen, J.E., Bruel, A., Jorgensen, N.R., Schwarz, P., 2013. The effect of PTH(1–34) on fracture healing during different loading conditions. *J. Bone Miner. Res. Off. J. Am. Soc. Bone Miner. Res.* 28 (10), 2145–2155.
- 59 Kim, H.W., Jahng, J.S., 1999. Effect of intermittent administration of parathyroid hormone on fracture healing in ovariectomized rats. *Iowa Orthop. J.* 19, 71–77.
- 60 Lin, J., Wu, J., Sun, S., Chen, K., Wu, H., Lin, R., Zhou, C., Kong, J., Zhou, K., Shui, X., 2020. Combined antiserotonin antibody and parathyroid hormone (1–34) synergistically enhance the healing of bone defects in ovariectomized rats. *Z. Gerontol. Geriatr.* 53 (2), 163–170.
- 61 Tao, Z.S., Lv, Y.X., Cui, W., Huang, Z.L., Tu, K.K., Zhou, Q., Sun, T., Yang, L., 2016. Effect of teriparatide on repair of femoral metaphyseal defect in ovariectomized rats. *Z. Gerontol. Geriatr.* 49 (5), 423–428.
- 62 Tsuchie, H., Miyakoshi, N., Kasukawa, Y., Anouma, H., Shimada, Y., 2013. Intermittent administration of human parathyroid hormone before osteosynthesis stimulates cancellous bone union in ovariectomized rats. *Tohoku J. Exp. Med.* 229 (1), 19–28.
- 63 Liu, G.Y., Cao, G.L., Tian, F.M., Song, H.P., Yuan, L.L., Geng, L.D., Zheng, Z.Y., Zhang, L., 2017. Parathyroid hormone (1–34) promotes fracture healing in ovariectomized rats with type 2 diabetes mellitus. *Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA* 28 (10), 3043–3053.
- 64 Tao, Z.S., Tu, K.K., Huang, Z.L., Zhou, Q., Sun, T., Xu, H.M., Zhou, Y.L., Lv, Y.X., Cui, W., Yang, L., 2016. Combined treatment with parathyroid hormone (1–34) and beta-tricalcium phosphate had an additive effect on local bone formation in a rat defect model. *Med. Biol. Eng. Comput.* 54 (9), 1353–1362.
- 65 Tao, Z.S., Zhou, W.S., Wu, X.J., Wang, L., Yang, M., Xie, J.B., Xu, Z.J., Ding, G.Z., 2019. Single-dose local administration of parathyroid hormone (1–34, PTH) with beta-tricalcium phosphate/collagen (beta-TCP/COL) enhances bone defect healing in ovariectomized rats. *J. Bone Miner. Metab.* 37 (1), 28–35.
- 66 Kitaguchi, K., Kashii, M., Ebina, K., Kaito, T., Okada, R., Makino, T., Etani, Y., Ishimoto, T., Nakano, T., Yoshikawa, H., 2020. The combined effects of teriparatide and anti-RANKL monoclonal antibody on bone defect regeneration in ovariectomized mice. *Bone* 130 (115077) no pagination.
- 67 Bruel, A., Olsen, J., Birkedal, H., Risager, M., Andreassen, T.T., Raffalt, A.C., Andersen, J.E., Thomsen, J.S., 2011. Strontium is incorporated into the fracture callus but does not influence the mechanical strength of healing rat fractures. *Calcif. Tissue Int.* 88 (2), 142–152.

- 68 Cebesoy, O., Tutar, E., Kose, K.C., Baltaci, Y., Bagci, C., 2007. Effect of strontium ranelate on fracture healing in rat tibia. *Joint Bone Spine* 74 (6), 590–593.
- 69 Li, Y.F., Luo, E., Feng, G., Zhu, S.S., Li, J.H., Hu, J., 2010. Systemic treatment with strontium ranelate promotes tibial fracture healing in ovariectomized rats. *Osteoporos. Int.* 21 (11), 1889–1897.
- 70 Komrakova, M., Weidemann, A., Dullin, C., Ebert, J., Tezval, M., Stuermer, K.M., Sehmisch, S., 2015. The impact of strontium ranelate on metaphyseal bone healing in ovariectomized rats. *Calcif. Tissue Int.* 97 (4), 391–401.
- 71 Ozturan, K.E., Demir, B., Yucel, I., Kacici, H., Yilmaz, F., Haberal, A., 2011. Effect of strontium ranelate on fracture healing in the osteoporotic rats. *J. Orthop. Res.* 29 (1), 138–142.
- 72 Li, Y.T., Cai, H.F., Zhang, Z.L., 2014. Timing of the initiation of bisphosphonates after surgery for fracture healing: a systematic review and meta-analysis of randomized controlled trials. *Osteoporos. Int.* 26 (2), 431–441.
- 73 Kim, T.Y., Ha, Y.C., Kang, B.J., Lee, Y.K., Koo, K.H., 2012. Does early administration of bisphosphonate affect fracture healing in patients with intertrochanteric fractures? *J. Bone Joint Surg. Br.* 94 (7), 956–960.
- 74 Colon-Emeric, C., Nordsletten, L., Olson, S., Major, N., Boonen, S., Haentjens, P., Mesenbrink, P., Magaziner, J., Adachi, J., Lyles, K.W., et al., 2011. Association between timing of zoledronic acid infusion and hip fracture healing. *Osteoporos. Int.* 22 (8), 2329–2336.
- 75 van der Poest, Clement E., Patka, P., Vandormael, K., Haarman, H., Lips, P., 2000. The effect of alendronate on bone mass after distal forearm fracture. *J. Bone Miner. Res.* 15 (3), 586–593.
- 76 Uchiyama, S., Itsubo, T., Nakamura, K., Fujinaga, Y., Sato, N., Imaeda, T., Kadoya, M., Kato, H., 2013. Effect of early administration of alendronate after surgery for distal radial fragility fracture on radiological fracture healing time. *Bone Joint J.* 95-B (11), 1544–1550.
- 77 Duckworth, A.D., McQueen, M.M., Tuck, C.E., Tobias, J.H., Wilkinson, J.M., Biant, L.C., Pulford, E.C., Aldridge, S., Edwards, C., Roberts, C.P., et al., 2019. Effect of alendronic acid on fracture healing: a multicenter randomized placebo-controlled trial. *J. Bone Miner. Res. Off. J. Am. Soc. Bone Miner. Res.* 34 (6), 1025–1032.
- 78 Gong, H.S., Song, C.H., Lee, Y.H., Rhee, S.H., Lee, H.J., Baek, G.H., 2012. Early initiation of bisphosphonate does not affect healing and outcomes of volar plate fixation of osteoporotic distal radial fractures. *J. Bone Joint Surg.* 94 (19), 1729–1736.
- 79 Hayer, P.S., Deane, A.K., Agrawal, A., Maheshwari, R., Juyal, A., 2017. Effect of zoledronic acid on fracture healing in osteoporotic patients with intertrochanteric fractures. *Int. J. Appl. Basic Med. Res.* 7 (1), 48–52.
- 80 Lim, E.J., Kim, J.T., Kim, C.H., Kim, J.W., Chang, J.S., Yoon, P.W., 2019. Effect of preoperative bisphosphonate treatment on fracture healing after internal fixation treatment of intertrochanteric femoral fractures. *Hip Pelvis* 31 (2), 75–81.
- 81 Cho, Y.J., Chun, Y.S., Rhyu, K.H., Kang, J.S., Jung, G.Y., Lee, J.H., 2015. Does the time of postoperative bisphosphonate administration affect the bone Union in Osteoporotic Intertrochanteric Fracture of Femur? *Hip & pelvis* 27 (4), 258–264.
- 82 Seo, J.B., Yoo, J.S., Ryu, J.W., Yu, K.W., 2016. Influence of early bisphosphonate administration for fracture healing in patients with osteoporotic proximal humerus fractures. *Clin. Orthop. Surg.* 8 (4), 437–443.
- 83 Shoji, K.E., Earp, B.E., Rozental, T.D., 2018. The effect of bisphosphonates on the clinical and radiographic outcomes of distal radius fractures in women. *J. Hand Surg.* 43 (2), 115–122.
- 84 Solomon, D.H., Hochberg, M.C., Mogun, H., Schneeweiss, S., 2009. The relation between bisphosphonate use and non-union of fractures of the humerus in older adults. *Osteoporos. Int.* 20 (6), 895–901.
- 85 Rozental, T.D., Vazquez, M.A., Chacko, A.T., Ayogu, N., Bouxsein, M.L., 2009. Comparison of radiographic fracture healing in the distal radius for patients on and off bisphosphonate therapy. *J. Hand Surg.* 34 (4), 595–602.
- 86 Koshy, N., Pinto, D., Sujir, P., Joe, V., Kamath, K.G., 2017. Effect of alendronate on the healing time of distal radial fractures treated conservatively: an observational study. *Asian J. Pharm. Clin. Res.* 10 (11), 168–172.
- 87 Adami, S., Libanati, C., Boonen, S., Cummings, S.R., Ho, P.R., Wang, A., Siris, E., Lane, J., Adachi, J.D., Bhandari, M., et al., 2012. Denosumab treatment in postmenopausal women with osteoporosis does not interfere with fracture-healing: results from the FREEDOM trial. *J. Bone Joint Surg. Am.* 94 (23), 2113–2119.
- 88 Han, S., Wen, S.M., Zhao, Q.P., Huang, H., Wang, H., Cong, Y.X., Shang, K., Ke, C., Zhuang, Y., Zhang, B.F., 2020. The efficacy of teriparatide in improving fracture healing in hip fractures: a systematic review and meta-analysis. *Biomed. Res. Int.* 2020, 5914502.
- 89 Huang, T.W., Chuang, P.Y., Lin, S.J., Lee, C.Y., Huang, K.C., Shih, H.N., Lee, M.S., Hsu, R.W., Shen, W.J., 2016. Teriparatide improves fracture healing and early functional recovery in treatment of osteoporotic intertrochanteric fractures. *Medicine (Baltimore)* 95 (19), e3626.
- 90 Huang, T.W., Yang, T.Y., Huang, K.C., Peng, K.T., Lee, M.S., Hsu, R.W., 2015. Effect of teriparatide on unstable pertrochanteric fractures. *Biomed. Res. Int.* 2015, 568390.
- 91 Kim, S.J., Park, H.S., Lee, D.W., Lee, J.W., 2019. Short-term daily teriparatide improve postoperative functional outcome and fracture healing in unstable intertrochanteric fractures. *Injury* 50 (7), 1364–1370.
- 92 Kim, S.J., Park, H.S., Lee, D.W., Lee, J.W., 2018. Does short-term weekly teriparatide improve healing in unstable intertrochanteric fractures? *J. Orthop. Surg. (Hong Kong)* 26 (3), 2309499018802485.
- 93 Bhandari, M., Jin, L., See, K., Burge, R., Gilchrist, N., Witvrouw, R., Krohn, K.D., Warner, M.R., Ahmad, Q.I., Mitlak, B., 2016. Does teriparatide improve femoral neck fracture healing: results from a randomized placebo-controlled trial. *Clin. Orthop. Relat. Res.* 474 (5), 1234–1244.
- 94 Chesser, T.J., Fox, R., Harding, K., Halliday, R., Barnfield, S., Willett, K., Lamb, S., Yau, C., Javadi, M.K., Gray, A.C., et al., 2016. The administration of intermittent parathyroid hormone affects functional recovery from trochanteric fractured neck of femur: a randomised prospective mixed method pilot study. *Bone Joint J.* 98-B, 840–845.
- 95 Hong, H., Song, T., Liu, Y., Li, J., Jiang, Q., Song, Q., Deng, Z., 2019. The effectiveness and safety of parathyroid hormone in fracture healing: a meta-analysis. *Clinics (Sao Paulo, Brazil)* 74, e800.
- 96 Peichl, P., Holzer, L.A., Maier, R., Holzer, G., 2011. Parathyroid hormone 1–84 accelerates fracture-healing in pubic bones of elderly osteoporotic women. *J. Bone Joint Surg.* 93 (17), 1583–1587.
- 97 Kanakaris, N.K., West, R.M., Giannoudis, P.V., 2015. Enhancement of hip fracture healing in the elderly: evidence deriving from a pilot randomized trial. *Injury* 46 (8), 1425–1428.
- 98 Almirol, E., Gao, L., Hurwitz, S., Khurana, B., Baima, J., Bluman, E., Chiodo, C., Leboff, M., 2013. Effects of recombinant human parathyroid hormone on the anabolic window and lower extremity stress fracture healing in premenopausal women: a pilot study. *J. Bone Miner. Res. Conf.* 28 (SUPPL 1).
- 99 Aspenberg, P., Genant, H.K., Johansson, T., Nino, A.J., See, K., Krohn, K., Garcia-Hernandez, P.A., Recknor, C.P., Einhorn, T.A., Dalsky, G.P., et al., 2010. Teriparatide for acceleration of fracture repair in humans: a prospective, randomized, double-blind study of 102 postmenopausal women with distal radial fractures. *J. Bone Miner. Res.* 25 (2), 404–414.
- 100 Johansson, T., 2016. PTH 1-34 (teriparatide) may not improve healing in proximal humerus fractures. A randomized, controlled study of 40 patients. *Acta Orthop.* 87 (1), 79–82.
- 101 Scaglione, M., Fabbri, L., Casella, F., Guido, G., 2016. Strontium ranelate as an adjuvant for fracture healing: clinical, radiological, and ultrasound findings in a randomized controlled study on wrist fractures. *Osteoporos. Int.* 27 (1), 211–218.
- 102 Yoon, B.H., Kim, K.C., 2020. Does teriparatide improve fracture Union?: A systematic review. *J. Bone Metab.* 27 (3), 167–174.
- 103 Watts, N.B., Aggers, D., McCarthy, E.F., Savage, T., Martinez, S., Patterson, R., Carrithers, E., Miller, P.D., 2017. Responses to treatment with teriparatide in patients with atypical femur fractures previously treated with bisphosphonates. *J. Bone Miner. Res.* 32 (5), 1027–1033.
- 104 Greenspan, S.L., Vujevic, K., Britton, C., Herradura, A., Gruen, G., Tarkin, I., Siska, P., Hamlin, B., Perera, S., 2018. Teriparatide for treatment of patients with bisphosphonate-associated atypical fracture of the femur. *Osteopor. Int.* 29 (2), 501–506.
- 105 Yeh, W.L., Su, C.Y., Chang, C.W., Chen, C.H., Fu, T.S., Chen, L.H., Lin, T.Y., 2017. Surgical outcome of atypical subtrochanteric and femoral fracture related to bisphosphonates use in osteoporotic patients with or without teriparatide treatment. *BMC Musculoskelet. Disord.* 18 (1), 527.
- 106 Miyakoshi, N., Aizawa, T., Sasaki, S., Ando, S., Maekawa, S., Aonuma, H., Tsuchie, H., Sasaki, H., Kasukawa, Y., Shimada, Y., 2015. Healing of bisphosphonate-associated atypical femoral fractures in patients with osteoporosis: a comparison between treatment with and without teriparatide. *J. Bone Miner. Metab.* 33 (5), 553–559.
- 107 Tsuchie, H., Miyakoshi, N., Iba, K., Kasukawa, Y., Nozaka, K., Dohke, T., Kosukegawa, I., Aizawa, T., Maekawa, S., Abe, H., et al., 2018. The effects of teriparatide on acceleration of bone healing following atypical femoral fracture: comparison between daily and weekly administration. *Osteoporos. Int.* 29 (12), 2659–2665.
- 108 Shin, W.C., Moon, N.H., Jang, J.H., Seo, H.U., Suh, K.T., 2019. A retrospective bicenter comparative study of surgical outcomes of atypical femoral fracture: Potential effect of teriparatide on fracture healing and callus formation. *Bone* 128 (115033) no pagination.
- 109 Gong, H.S., 2012. Early initiation of bisphosphonate does not affect healing and outcomes of volar plate fixation of osteoporotic distal radius fractures. *Osteoporos. Int.* S817–S818.